Vivek Subbiah on Muck Rack

Vivek Subbiah

Nashville
As seen in: Color Research & Application, Nature, Wiley Online Library, ScienceDirect, The Oncologist, MDPI, SAGE Publishing, Biomed Central (BMC), JAMA (The Journal of the American Medical Association), JAMA Oncology and
Drug Development| Precision Oncology| Tissue-Agnostic Precision Medicine #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vivek

Contact Vivek, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mutation-centric kinase drug repurposing for rare cancers

|
By Marina Chan, Haiching Ma, Vivek Subbiah, Taranjit S Gujral
| Nature
Rare cancers remain underserved by precision oncology, in part because many oncogenic variants lack matched therapies despite a growing arsenal of targeted drugs. We propose that systematic, variant-level pharmacological mapping of approved kinase inhibitors can transform this gap into an opportunity for scalable drug repurposing.
Open in Who Shared Issue with article?

Closing the paediatric gap in cancer drug development: a call to industry

|
By Vivek Subbiah, Branko Cuglievan
| Nature
COMMENT 29 May 2026 Despite transformative advances in adult oncology, children with cancer remain systematically underserved by drug development pipelines. We argue that sequential, siloed paediatric development is no longer defensible. Integrating paediatric considerations from drug discovery onwards, and leveraging tumour-agnostic trial designs, regulatory frameworks and adaptive methodologies, offers sponsors superior science, cleaner regulatory pathways and broader patient impact.
Open in Who Shared Issue with article?

Delivering Precision Oncology at Scale—Infrastructure, Evidence, and the Path Forward

|
By Vivek Subbiah
| JAMA Oncology
In their study in this issue of JAMA Oncology,1 Lin and colleagues report findings from Australia’s Molecular Screening and Therapeutic (MoST) program. This cohort study examined 3383 patients with advanced, refractory cancers who underwent comprehensive genomic profiling.
Open in Who Shared Issue with article?
See all 164 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Vivek

Contact Vivek, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified